NCT01466647View on ClinicalTrials.gov

A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC)

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

AXL1717

A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods

Trial Locations (2)

Unknown

KFUE, Uppsala

University Hospital, Uppsala

Sponsors

Lead Sponsor

Axelar AB
All Listed Sponsors
lead

Axelar AB

INDUSTRY

NCT01466647 - A Study of the IGF-1R Inhibitor AXL1717 in Combination With Gemcitabine HCL and Carboplatin to Treat Non-small-cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter